Annovis Bio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 6
- Market Cap
- $119.1M
- Website
- http://www.annovisbio.com
- Introduction
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.
FDA Accepts Final Protocol For Annovis Bio's Pivotal Phase 3 Alzheimer Study
Annovis Bio's FDA-accepted protocol for a Phase 3 Alzheimer's study combines two trials into one, starting January 2025. The 6/18-month study evaluates buntanetap's symptomatic and disease-modifying effects, aiming for NDA filing with 6-month data. CEO Maria Maccecchini highlights the design's potential for early-stage Alzheimer's treatment.
Press Release: Annovis Bio, Inc. Invites Subscriptions for Updates on Neurodegenerative Disease Research
Annovis Bio, Inc. (NYSE: ANVS) invites individuals to subscribe to their newsletter for updates on innovative research and advancements in treating neurodegenerative diseases, including Alzheimer's and Parkinson's.
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer's Study
FDA accepted Annovis Bio's updated protocol for a pivotal Phase 3 Alzheimer’s study, merging two trials into one 6/18-month trial to assess buntanetap's symptomatic and disease-modifying effects, aiming for a New Drug Application filing with 6-month data.
Roche's Parkinson's hope fails second clinical trial
Roche and Prothena's prasinezumab, targeting alpha-synuclein for Parkinson's, missed primary endpoint in phase 2b PADOVA trial but showed numerical delay in motor progression and positive trends on secondary endpoints. Roche plans further exploration and collaboration with Parkinson's community.
UCB drops Parkinson's treatment after ORCHESTRA trial failed all endpoints
UCB is discontinuing minzasolmin development for Parkinson’s disease after the ORCHESTRA study failed to meet endpoints. The company will focus on glovadalen (UCB0022) for symptom treatment. Stock prices briefly dropped but later recovered.
Parkinson's Disease Market is Expected to Showcase a
Parkinson's disease market to grow at 5.8% CAGR (2020-2034) due to advancements in diagnostics, increased awareness, and a rising number of cases. Emerging therapies like Supernus/Britannia's SPN-830, AbbVie's tavapadon, and Pharma Two B's P2B001 could significantly impact market dynamics. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size (2020-2034) for 7MM.
© Copyright 2025. All Rights Reserved by MedPath